TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV, L3
Earnings Release
Shareholder votes
News, Securities Holder Rights or Indentures, Description of Registrant's Securities, Legal Opinion
Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes
Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
Annual Report to Security Holders
Teva Announces Growth and Strong 2024 Financial Results
Changes in Board, Management or Compensation
Q1
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
Free Writing Prospectus